Delaying the Medicare rebate rule is a step in the right direction for patients struggling to afford their prescription medication. But preventing cost-shifting is not a substitute for real reforms that rein in drug corporations’ monopoly power to raise prices anytime they want.
Wild has sent a letter to Democratic leadership urging them to include Medicare negotiation power in the upcoming reconciliation bill.
This settlement makes a mockery of justice. While four of the most profitable drug corporations in the world agree to share a fraction of their profits with victims of opioids, not one of the executives responsible for this epidemic is being held accountable.
A Green Bay resident writes in support of HR3, a Democratic bill that would enact several measures to lower drug costs.
A chance for meaningful drug pricing reform is upon us, dozens of purchasers, healthcare and employer groups contend. But Congress needs to capitalize on its “time-limited” opportunity, or the problem could stagnate or worsen.
As a retired Air Force veteran who spent 24 years serving my country, I understand what it’s like to fight for the basics. Millions of veterans have sacrificed and contributed in countless ways to protect freedoms, ensure security and save lives through the years.
These actions by President Biden — importation and ending pay-for-delay on generics — are helpful steps to increase competition and access for patients on some drugs. But these steps alone won’t fundamentally solve the problem of price gouging by pharmaceutical corporations that have monopoly power to set and increase prices whenever they want.